Table 1.
Baseline characteristics of all patients and divided by starting on MTX monotherapy or not
| Characteristics | All patients N = 219 |
Patients starting on MTX therapy N = 183 |
Patients not starting on MTX therapy N = 36 |
|---|---|---|---|
| Demographics | |||
| Age (years) | 53±14 | 53±14 | 51±16 |
| Male (%) | 110 (50) | 93 (51) | 17 (47) |
| BMI (kg/m2) | 28.4±5.0 | 28.4±4.8 | 28.6±5.8 |
| Symptom duration (self-reported, months) |
10 (4–29) | 10 (4–27) | 6.4 (4.1–84) |
| Baseline disease scores | |||
| Oligoarthritis (%) | 134 (61) | 108 (59) | 26 (72) |
| Polyarthritis (%) | 85 (39) | 75 (41) | 10 (28) |
| Tender joint count | 5 (2–10) | 5 (2–10) | 4 (2–10) |
| Swollen joint count | 3 (2–6) | 4 (2–6) | 2 (1–4.5) |
| Elevated CRP >10 mg/L | 67 (37) | 61 (40) | 6 (20) |
| PASI | 2.4 (0.6–4.6) | 2.5 (0.7–4.7) | 1.3 (0.4–4.5) |
| Pain VAS | 48±27 | 49±26 | 47±31 |
| Global VAS | 47±25 | 48±25 | 39±28 |
| LEI >0 (%) | 82 (39) | 70 (38) | 15 (42) |
| Dactylitis (%) | 35 (16) | 32 (17) | 3 (8) |
| HAQ total score | 0.8 (0.4–1.1) | 0.8 (0.4–1.0) | 0.6 (0.3–1.1) |
| Medication | |||
| MTX starting dosage (mg), (%) | |||
| 7.5 | 2 (1) | ||
| 10 | 13 (7) | ||
| 15 | 93 (51) | ||
| 20 | 9 (5) | ||
| 25 | 58 (32) | ||
Results shown as mean±SD, n (%) or median (IQR). Baseline clinical data of one patient missing, questionnaires of five patients are missing.
BMI, body mass index; CRP C reactive protein; HAQ, Health Assessment Questionnaire; LEI, Leeds Enthesitis Index; MTX, methotrexate; PASI, Psoriasis Area and Severity Index; VAS, Visual Analogue Scale.